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Key Points: 38 
Chronic asymptomatic P. falciparum infection during the dry season predicts decreased clinical 39 
malaria risk during the ensuing malaria season; however, treating these infections did not alter this 40 
reduced risk, challenging the notion that chronic P. falciparum infection maintains malaria immunity.  41 
 42 
  43 
 3 
Abstract 44 
Background Chronic asymptomatic Plasmodium falciparum infections are common in endemic areas 45 
and are thought to contribute to the maintenance of malaria immunity. Whether treatment of these 46 
infections increases the subsequent risk of clinical episodes of malaria is unclear.  47 
Methods In a three-year study in Mali, asymptomatic individuals with or without P. falciparum 48 
infection at the end of the six-month dry season were identified by PCR, and clinical malaria risk was 49 
compared during the ensuing six-month malaria transmission season. At the end of the second dry 50 
season, three groups of asymptomatic children were identified: 1) children infected with P. falciparum 51 
as detected by rapid diagnostic testing (RDT) who were treated with antimalarials (n=104), 2) RDT-52 
negative children whose untreated P. falciparum infections were detected retrospectively by PCR 53 
(n=55), and 3) uninfected children (RDT/PCR negative) (n=434). Clinical malaria risk during two 54 
subsequent malaria seasons was compared. P. falciparum-specific antibody kinetics during the dry 55 
season were compared in children who did or did not harbour asymptomatic P. falciparum infections.  56 
Results Chronic asymptomatic P. falciparum infection predicted decreased clinical malaria risk 57 
during the subsequent malaria season(s); treatment of these infections did not alter this reduced risk. P. 58 
falciparum-specific antibodies declined similarly in children who did or did not harbour chronic 59 
asymptomatic P. falciparum infection during the dry season.  60 
Conclusions These findings challenge the notion that chronic asymptomatic P. falciparum infection 61 
maintains malaria immunity and suggest that mass drug administration during the dry season should 62 
not increase the subsequent risk of clinical malaria.   63 
 4 
Introduction 64 
 65 
Plasmodium falciparum is responsible for ~200 million cases of malaria and 400,000 deaths annually 66 
[1]. Encouragingly, the scale up of mosquito control measures and artemisinin-based combination 67 
therapy has been associated with reduced malaria burden in many regions [2]. Consequently, an 68 
increasing number of endemic countries are working towards elimination and considering the 69 
interventions that will be required to achieve this objective. Importantly, a large proportion of people 70 
in endemic areas are infected with P. falciparum without symptoms [3, 4]. This clinically silent 71 
parasite reservoir, which persists for months to years [5] and contributes to ongoing malaria 72 
transmission [4, 6-9], poses a challenge for elimination efforts. The strategies of antimalarial mass 73 
drug administration (MDA) to at risk populations or mass screening and treatment (MSAT) of 74 
asymptomatically infected individuals are being considered in certain settings [10-12], particularly in 75 
areas of seasonal transmission where MDA during the dry season could reduce the number of 76 
gametocyte carriers and decrease transmission to the mosquito vector as the rainy season ensues [11, 77 
13, 14]. 78 
 79 
However, asymptomatic P. falciparum infections have long been thought to directly contribute to the 80 
maintenance of immunity to malaria, a notion referred to as ‘premunition’ [15-17]. Consistent with 81 
this hypothesis, studies in areas of seasonal malaria have shown that asymptomatic P. falciparum 82 
infection at the end of the dry season predicts decreased risk of febrile malaria during the ensuing 83 
malaria season [18-22]. This raises the question of whether treatment of asymptomatic infections 84 
during the dry season might increase the risk of symptomatic malaria in the event of P. falciparum re-85 
infection. 86 
 87 
Two studies in areas of seasonal malaria assessed the impact of treating asymptomatic P. falciparum 88 
infection during the dry season on the subsequent risk of clinical malaria. A trial in the Gambia 89 
randomized villages to placebo versus one dose of sulfadoxine-pyrimethamine combined with one 90 
dose of artesunate and found no difference in malaria incidence during 20 weeks of follow-up, 91 
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although there was a significant drop in the incidence of malaria during the period immediately after 92 
drug administration [23]. Similarly, a trial in Burkina Faso randomized villages to screening and 93 
treatment of asymptomatic P. falciparum infection with artemether-lumefantrine (AL) or no 94 
intervention and found no difference in the subsequent incidence of malaria [24]. In contrast, a study 95 
in the Zambia—where malaria transmission is year-round—randomized health districts during the low 96 
transmission season to screening and treatment of infected individuals with AL or no intervention and 97 
found a modest decrease in malaria risk in the intervention group [25].  98 
 99 
Importantly, these studies compared malaria risk at the community rather than individual level, which 100 
may have confounded the results due to heterogeneity in P. falciparum transmission across 101 
communities. Additionally, at the time of treatment these studies did not distinguish chronic 102 
asymptomatic P. falciparum infection from recently transmitted infections that may have progressed 103 
to clinical malaria without treatment [26], and which may have different effects on host immunity. 104 
Together, the limitations of these studies leave open the question of whether treatment of chronic 105 
asymptomatic P. falciparum infection impacts the subsequent risk of clinical malaria at the individual 106 
level. 107 
 108 
In this longitudinal study conducted in an area of seasonal malaria we addressed four objectives: 1) 109 
determine whether asymptomatic P. falciparum parasitemia detected at the end of the six-month dry 110 
season represents chronic infection, 2) confirm that asymptomatic P. falciparum infections during the 111 
dry season predict protection from clinical malaria during the ensuing malaria season, 3) determine the 112 
impact of treating asymptomatic P. falciparum infection during the dry season on the subsequent risk 113 
of clinical malaria, and 4) determine whether chronic asymptomatic P. falciparum infection maintains 114 
P. falciparum-specific humoral immunity. 115 
 116 
METHODS 117 
 118 
Ethics statement  119 
 6 
The Ethics Committee of the FMPOS at the University of Bamako, and the NIAID/NIH IRB approved 120 
this study. Written informed consent was obtained from all subjects and the parents/guardians of 121 
participating children. The study is registered on http://www.clinicaltrials.gov (NCT01322581). 122 
 123 
Study design and participants  124 
From May 2011 through December 2013 a cohort study was conducted in Kalifabougou, Mali, a rural 125 
village of ~5000 inhabitants where malaria transmission occurs from July through December. A single 126 
clinic and pharmacy provided the only access to antimalarial drugs. A detailed description of the study 127 
site and cohort design has been published elsewhere [27]. From an age-stratified, random sample of 128 
the entire village population, 695 healthy individuals aged six months to 25 years were enrolled. 129 
Exclusion criteria were haemoglobin concentration <7 g/dL, axillary temperature ≥37.5°C, acute 130 
systemic illness, or use of antimalarial or immunosuppressive medications in the preceding 30 days. 131 
Clinical malaria episodes were detected prospectively by active and passive surveillance and were 132 
defined by an axillary temperature of ≥37.5°C, ≥2500 asexual parasites/μL of blood, and no other 133 
cause of fever on physical examination.  134 
 135 
Detection of P. falciparum infection 136 
Thick blood smears were stained with Giemsa and Plasmodium parasites were counted against 300 137 
leukocytes; parasite densities were recorded as the number of parasites/µL of whole blood based on a 138 
mean leukocyte count of 7500 cells/µL. Two expert microscopists evaluated each smear separately, 139 
and a third resolved discrepancies. The First Response® Combo Malaria Ag (pLDH/HRP2) card was 140 
used as a rapid diagnostic test (RDT), the sensitivity of which is ~100 parasites/μl [28]. Nested PCR 141 
amplification of Plasmodium DNA was performed from dried blood spots as previously described 142 
[27], the sensitivity of which is ~0.5 - 1 parasites/μl [27].  143 
 144 
Additional methods are described online in supplementary information. 145 
 146 
Results 147 
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 148 
Asymptomatic P. falciparum infection during the dry season is associated with lower risk of 149 
clinical malaria during the ensuing malaria season 150 
 151 
We sought to confirm prior studies that associated asymptomatic P. falciparum infection with lower 152 
risk of clinical malaria [18, 19, 21, 22]. During a two-week period in May 2011 we enrolled 695 153 
asymptomatic subjects just prior to the 6-month malaria season (Figure 1A). The prevalence of P. 154 
falciparum infection at enrolment was 45.6% by PCR and 26.3% by blood smear. The prevalence of 155 
infection by PCR plateaued by 8 years of age, while the prevalence by blood smear declined after 8 156 
years of age (Figure 1B), consistent with an age-dependent decrease in parasitemia [27].  157 
 158 
During the ensuing six-month malaria season, clinical malaria episodes were detected by weekly 159 
active surveillance and self-referral. Consistent with prior studies [18-22], asymptomatic P. 160 
falciparum infection at the end of the dry season was associated with lower risk of febrile malaria 161 
during the ensuing malaria season (p<0.0001; Figure 1C), an association that remained significant 162 
after adjusting for age, gender and hemoglobin (Hb) type (P<0.0001; Figure 1D). The risk of febrile 163 
malaria was not significantly different between PCR+smear+ subjects and PCR+smear– subjects 164 
(p=0.51; Figure 1C), indicating that the difference in baseline parasitemia between these groups did 165 
not affect subsequent malaria risk. Hereafter, all analyses focus on children ≤11 years of age—the age 166 
group that experiences the majority of clinical malaria episodes in this cohort [27]. 167 
 168 
Treatment of chronic asymptomatic P. falciparum infection does not change the risk of clinical 169 
malaria during the subsequent malaria season 170 
 171 
The association between asymptomatic P. falciparum infection during the dry season and subsequent 172 
protection from febrile malaria suggests that treatment of asymptomatic infection at the end of the dry 173 
season could increase the risk of clinical malaria during the ensuing malaria season. To test this 174 
hypothesis, we screened the same cohort for P. falciparum infection (all asymptomatic) at the end of 175 
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the second dry season (May 2012) using an RDT with a sensitivity comparable to blood smear [29]. 176 
All subjects found to be P. falciparum-infected by RDT (n=104) were treated with a standard 3-day 177 
course of AL, the first daily dose of which was directly observed by study staff. Dried blood spots 178 
collected from RDT– subjects at the same timepoint (n=489) were later analyzed by PCR to 179 
retrospectively identify two additional groups that did not receive antimalarials: RDT–PCR+ subjects 180 
(n=55) and RDT–PCR– subjects (n=434).  181 
 182 
Because asymptomatic P. falciparum infections detected during cross-sectional surveys can become 183 
symptomatic within days or weeks of initial detection [3, 4, 30], we sought to confirm that P. 184 
falciparum infections detected at the end of the dry season in May 2012 were chronic and 185 
asymptomatic. We found that subjects infected with P. falciparum in May 2012 were highly likely to 186 
have been infected at the start of the dry season (January 2012) [OR: 842.6 c.i. (200.2, 3546.3), P < 187 
0.0001]; and through the mid-dry season (March 2012) [OR: 172.9 c.i. (79.8, 374.5), P < 0.0001]; and 188 
conversely, uninfected subjects at the start of the dry season remained uninfected at the end of the dry 189 
season (Supplementary Figure 1). During the same time period, no cases of clinical malaria were 190 
detected. We also examined parasites collected in January and May 2012, from individuals who tested 191 
PCR+ in May 2012, for 6 microsatellite loci previously used to characterize the genetic diversity of P. 192 
falciparum [31], and we obtained low Fst values between the populations (Fst January vs. May = 0.004), 193 
indicating that the two populations were genetically very similar (Figure 2A). Additionally, analysis of 194 
the polymorphic region of the P. falciparum msp2 locus in January and May 2012 indicated that 195 
asymptomatic infections were polyclonal at both timepoints and 47% of subjects harboured at least 196 
one common parasite clone at both timepoints (Figure 2B). Together with our observation that the 197 
entomological inoculation rate is near zero during the dry season, these data indicate that 198 
asymptomatic P. falciparum infections detected at the end of the dry season had persisted as chronic 199 
asymptomatic infections throughout the preceding dry season. 200 
 201 
The characteristics of the three groups defined in May 2012 (RDT+ treated, RDT–PCR+ untreated, and 202 
RDT–PCR– untreated) are shown in Table 1. Consistent with the first year of the study, the RDT–PCR– 203 
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group had the highest risk of febrile malaria during the second malaria season (Figure 3A), while 204 
febrile malaria risk in the RDT+ treated and RDT–PCR+ untreated groups was similar in both 205 
univariate (Figure 3A) and multivariate analyses (Figure 3B). We observed the same pattern during 206 
the third malaria season (Figure 3C and 3D), indicating that treatment of chronic asymptomatic P. 207 
falciparum infection at the end of the dry season does not change the risk of clinical malaria during 208 
two subsequent malaria seasons.  209 
 210 
P. falciparum-specific humoral immunity decreases similarly with or without chronic 211 
asymptomatic infection 212 
 213 
Because treatment of asymptomatic P. falciparum infection at the end of the dry season did not 214 
increase the subsequent risk of febrile malaria, we hypothesized that chronic asymptomatic P. 215 
falciparum infection per se does not maintain malaria immunity, but is instead a marker of higher past 216 
P. falciparum exposure and thus higher cumulative immunity. We tested this hypothesis by comparing 217 
antibody responses to 862 P. falciparum proteins before and after the dry season in age-matched 218 
children who did or did not harbour asymptomatic P. falciparum over the same time period. At both 219 
timepoints the breadth and magnitude of P. falciparum-specific antibodies were higher in subjects 220 
who carried parasites through the dry season (Figure 4A-C); however, both antibody breadth and 221 
magnitude decreased similarly during the dry season in infected and uninfected subjects (Figures 4D 222 
and 4E), suggesting that chronic asymptomatic P. falciparum infection per se does not contribute 223 
significantly to the maintenance of humoral immunity to malaria.  224 
 225 
Discussion 226 
 227 
Here we investigated the impact of treating chronic asymptomatic P. falciparum at the end of the dry 228 
season on the subsequent risk of clinical malaria. In doing so we tested the long-standing hypothesis 229 
that asymptomatic P. falciparum infection maintains immunity to malaria [15-17, 32, 33]. We found 230 
that treatment of asymptomatic P. falciparum infection at the end of the dry season did not increase 231 
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clinical malaria risk at the individual level during two subsequent malaria seasons. Moreover, P. 232 
falciparum-specific antibodies declined at a similar rate in children who did or did not harbour 233 
asymptomatic P. falciparum over the dry season. Together these findings challenge the notion that 234 
asymptomatic P. falciparum infection maintains clinical and humoral immunity to malaria and suggest 235 
that MDA during the dry season should not increase the subsequent risk of clinical malaria at the 236 
individual level. In contrast, seasonal malaria chemoprevention (SMC) [34] - which prevents the 237 
progression of new blood-stage infections during the transmission season - has been associated in 238 
some studies with increased malaria risk (i.e. rebound) after discontinuation of SMC [35, 36]. 239 
Therefore, we hypothesize that recently transmitted P. falciparum parasites more effectively induce 240 
immune responses relative to parasites that have persisted in blood for several months during the dry 241 
season. A differential capacity to trigger host immune responses could reflect epigenetic, 242 
transcriptional and metabolic differences between newly transmitted parasites and parasites that persist 243 
during long periods of asexual replication in blood.  244 
 245 
We found that the breadth and magnitude of IgG specific for 862 P. falciparum proteins/polypeptides 246 
declined at a similar rate in children who did or did not carry asymptomatic P. falciparum infection 247 
during the dry season. Similarly,Consistent with our antibody data, a study comparing Gambian 248 
children who did or did not carry P. falciparum parasites during the dry season found no difference in 249 
the rate of decline of IgG specific for three P. falciparum merozoite antigens (AMA1, EBA175, 250 
MSP119), whereas IgG specific for the merozoite antigen MSP2 declined more rapidly in uninfected 251 
children [37], suggesting interactions between specific antigens and infection status that require 252 
further investigation. We cannot exclude a role for chronic P. falciparum infection in maintaining 253 
other facets of host immunity such as cell-mediated immunity or regulatory mechanisms that attenuate 254 
malaria-induced inflammation. Our prior work in Mali suggests that asymptomatic infection during 255 
the dry season maintains P. falciparum-inducible IL-10 production capacity in some individuals; 256 
however, the magnitude of this response is much lower than that observed in the same children during 257 
the preceding transmission season one week after acute febrile malaria [38]. This is consistent with 258 
other studies in this population that showed a marked increase in P. falciparum-specific memory B 259 
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cells and antibodies during acute malaria that waned rapidly during the subsequent dry season [39, 260 
40]. Together these observations suggest that the maintenance of malaria immunity depends on 261 
repeated exposures to newly transmitted parasites.  262 
 263 
Of note, we observed no difference in baseline Hb levels among uninfected subjects and 264 
asymptomatically infected subjects, possibly explained in part by the exclusion of subjects with Hb <7 265 
g/dL from this study. Moreover, treatment of asymptomatic P. falciparum infection did not change the 266 
prevalence of anemia one year later (Supplementary Figure 2), which is consistent with a study in 267 
Kenya [41], but at odds with other studies [24, 42].  268 
 269 
This study has limitations. First, subjects were not blinded to treatment status, which could have led to 270 
differences in treatment seeking behavior. However, this was likely mitigated by weekly active 271 
surveillance for symptomatic malaria. Second, subjects were not randomized to treatment or no 272 
treatment groups, but were classified as such based on the RDT result at the end of the dry season, 273 
which may have led to differences between groups in known and unknown factors that affect malaria 274 
risk. The most important factors known to influence malaria risk in this cohort are age and Hb type 275 
[43], which did not differ significantly between the RDT+ treated and RDT–PCR+ untreated groups. 276 
Moreover, subjects who were blood smear+ or blood smear–PCR+ at the end of the first dry season had 277 
the same risk of clinical malaria during the first year of the study. Although we did not control for 278 
socioeconomic factors, the study population was an age-stratified random sample of individuals 279 
residing in a rural community where socioeconomic conditions are relatively uniform and where the 280 
research clinic was the only local source of antimalarials. Moreover, it seems unlikely that 281 
socioeconomic factors confounded the results such that children who were infected with P. falciparum 282 
before the malaria season were more likely to experience malaria during the transmission season, since 283 
we observed the opposite effect in this study. Thirdly, a larger study may have detected smaller 284 
differences in the risk of clinical malaria between groups. Finally, the average age of the RDT+ treated 285 
and RDT–PCR+ untreated groups was ~8 years, so further studies are needed to determine the impact 286 
of treating chronic asymptomatic P. falciparum infection in younger children. 287 
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 288 
Recent studies in endemic areas have shown that more sensitive detection methods reveal larger 289 
reservoirs of asymptomatic P. falciparum infection than previously appreciated [44, 45]. Therefore, it 290 
is possible that some subjects in this study had parasite densities below the detection limit of our PCR 291 
assay. However, the primary objective of this study was to compare febrile malaria risk in RDT+ 292 
treated subjects vs. RDT-PCR+ untreated subjects, so the possibility that some PCR- subjects were 293 
infected is unrelated to the major conclusions of this study. Moreover, if a significant proportion of 294 
PCR- subjects were actually infected, it would be difficult to reconcile their superior ability to 295 
suppress parasitemia during the dry season with their lower breadth and magnitude of P. falciparum-296 
specific antibodies and higher risk of febrile malaria during the ensuing malaria season.  297 
 298 
Because this study does not support a causal link between chronic asymptomatic P. falciparum 299 
infection and protection from febrile malaria, the question remains: what underlies the association 300 
between asymptomatic infection and decreased malaria risk? Longitudinal analysis of P. falciparum-301 
specific IgG responses in this study suggest that asymptomatic infection during the dry season is 302 
simply a marker of higher past P. falciparum exposure and thus higher cumulative humoral immunity 303 
to malaria. It is also possible that the protective immunomodulatory effects of asymptomatic infection 304 
persist beyond antimalarial treatment at the end of the dry season into the subsequent transmission 305 
season—a possibility that could be tested by treating asymptomatic infections at the beginning of the 306 
dry season and ensuring that clearance is sustained by repeated screening and MDA.  307 
 308 
In summary, treatment of chronic asymptomatic P. falciparum infection at the end of the dry season 309 
did not change the subsequent risk of clinical malaria, and P. falciparum-specific antibodies declined 310 
similarly in children who did or did not harbour chronic asymptomatic P. falciparum infection during 311 
the dry season. These findings challenge the notion that chronic asymptomatic P. falciparum infection 312 
maintains malaria immunity and suggest that MDA during the dry season may not increase the 313 
subsequent risk of clinical malaria at the individual level. 314 
 315 
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Table 1. Characteristics of study participants stratified by infection status at the end of 441 
the second dry season. 442 
 443 
  444 
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Figure Legends 445 
Figure 1. Asymptomatic P. falciparum infection at the end of the dry season 446 
independently predicts decreased febrile malaria risk during the ensuing malaria 447 
season. (A) Frequency of clinical malaria episodes every 2 days over three years in a cohort 448 
of 695 subjects aged 3 mos - 25 yrs. Clinical malaria defined as axillary temperature ≥37.5°C, 449 
≥2500 asexual parasites/μL of blood and no other cause of fever discernible on physical 450 
exam. (B) Age-stratified point prevalence of asymptomatic P. falciparum infection detected 451 
by PCR or blood smear at the end of the dry season in May 2011. (C) Kaplan-Meier analysis 452 
of time to first febrile malaria episode during the 2011 malaria season stratified by P. 453 
falciparum infection status in May 2011. Pairwise comparisons by log rank test: PCR+smear+ 454 
vs. PCR–smear–(p<0.0001); PCR+smear– vs. PCR–smear- (p<0.0001); PCR+smear+ vs. 455 
PCR+smear– (p=0.51). (D) Cox model showing the effect of P. falciparum infection status in 456 
May 2011 on the risk of febrile malaria during the ensuing 2011 malaria season, adjusted for 457 
covariates. Hazard ratios and 95% confidence intervals are represented by open circles and 458 
horizontal bars, respectively.  459 
 460 
Figure 2. Genetic evidence that P. falciparum infections persist throughout the six-461 
month dry season. (A) Six P. falciparum microsatellite loci were examined in peripheral 462 
blood samples collected from 91 P. falciparum-infected subjects in January and May 2012. 463 
Each color represents different allele sizes after adjustment to 3 bp bins. (B) Proportion of 464 
subjects with different number of P. falciparum clones determined by size differences in the 465 
polymorphic region of msp2 in January (n=124) and May 2012 (n=128) and overlapping at 466 
the two cross-sectional timepoints (n=90) in the respective age groups. 467 
 21 
Figure 3. Treatment of chronic asymptomatic P. falciparum infection does not change 468 
the subsequent risk of febrile malaria. (A) Kaplan-Meier analysis of time to first febrile 469 
malaria episode during the 2012 malaria season stratified by P. falciparum infection and 470 
treatment status at the end of the dry season in May 2012. Pairwise comparisons by log rank 471 
test: RDT+/treated vs. PCR– (p<0.0001); RDT–PCR+/untreated vs. PCR– (p<0.0001); 472 
RDT+/treated vs. RDT–PCR+/untreated (p=0.26). (B) Cox model showing the effect of P. 473 
falciparum infection and treatment status in May 2012 on the risk of febrile malaria during 474 
the ensuing 2012 malaria season, adjusted for covariates. (C) Kaplan-Meier analysis of time 475 
to first febrile malaria episode during the 2013 malaria season stratified by P. falciparum 476 
infection and treatment status at the end of the dry season in May 2012. Pairwise comparisons 477 
by log rank test: RDT+/treated vs. PCR– (p<0.0001); RDT–PCR+/untreated vs. PCR– 478 
(p<0.0001); RDT+/treated vs. RDT–PCR+/untreated (p=0.066). (D) Cox model showing the 479 
effect of P. falciparum infection and treatment status in May 2012 on the risk of febrile 480 
malaria during the 2013 malaria season, adjusted for covariates. Hazard ratios and 95% 481 
confidence intervals are represented by open circles and horizontal bars, respectively. 482 
 483 
Figure 4. P. falciparum-specific IgG reactivity decreases during the dry season 484 
irrespective of P. falciparum infection status. (A) Breadth of IgG response in January and 485 
May 2012 stratified by P. falciparum infection status in May 2012. (B) Magnitude of IgG 486 
reactivity in January and May 2012 stratified by P. falciparum infection status in May 2012. 487 
(C) Magnitude of IgG response in January and May 2012 for antigens that were reactive at 488 
both timepoints (2 SDs above the no DNA control), stratified by P. falciparum infection 489 
status in May 2012. (D) Proportion of antigens to which the level of IgG reactivity fell below 490 
the level of detection between January and May 2012 stratified by P. falciparum infection 491 
status in May 2012. (E) Change in magnitude of IgG reactivity for antigens that were reactive 492 
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in January and May 2012, stratified by P. falciparum infection status in May 2012. Breadth is 493 
defined as the number of antigens to which the level of IgG reactivity exceeds 2 SDs above 494 
the no DNA control. Magnitude is defined as the sum of log2-IgG intensity values for all 495 
antigens per sample. Boxes indicate median, 25th and 75th percentiles. Values greater than 1.5 496 
times the IQR are plotted as individual points (Tukey’s method). 497 
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